Correlation Engine 2.0
Clear Search sequence regions

  • blood (2)
  • CCK (2)
  • cck 8 (9)
  • CCK1 (1)
  • cholesterol levels (1)
  • diet high- fat (1)
  • exendin 4 (5)
  • glp 1 receptors (1)
  • GLP- 1 (4)
  • Glucagon (2)
  • hybrid (5)
  • insulin (5)
  • locomotor activity (1)
  • mice (5)
  • obesity (1)
  • parent (1)
  • peptides (4)
  • plasma (3)
  • receptors (1)
  • venoms (2)
  • vitro (1)
  • weight (1)
  • Sizes of these terms reflect their relevance to your search.

    Glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) exert important complementary beneficial metabolic effects. This study assessed the biological actions and therapeutic utility of a novel (pGlu-Gln)-CCK-8/exendin-4 hybrid peptide compared with the stable GLP-1 and CCK mimetics exendin-4 and (pGlu-Gln)-CCK-8, respectively. All peptides significantly enhanced in vitro insulin secretion. Administration of the peptides, except (pGlu-Gln)-CCK-8 alone, in combination with glucose significantly lowered plasma glucose and increased plasma insulin in mice. All treatments elicited appetite-suppressive effects. Twice-daily administration of the novel (pGlu-Gln)-CCK-8/exendin-4 hybrid, (pGlu-Gln)-CCK-8 alone, or (pGlu-Gln)-CCK-8 in combination with exendin-4 for 21 days to high-fat-fed mice significantly decreased energy intake, body weight, and circulating plasma glucose. HbA1c was reduced in the (pGlu-Gln)-CCK-8/exendin-4 hybrid and combined parent peptide treatment groups. Glucose tolerance and insulin sensitivity also were improved by all treatment modalities. Interestingly, locomotor activity was decreased in the hybrid peptide group, and these mice also exhibited reductions in circulating triglyceride and cholesterol levels. Pancreatic islet number and area, as well β-cell area and insulinotropic responsiveness, were dramatically improved by all treatments. These studies highlight the clear potential of dual activation of GLP-1 and CCK1 receptors for the treatment of type 2 diabetes. © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.


    Nigel Irwin, Varun Pathak, Peter R Flatt. A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice. Diabetes. 2015 Aug;64(8):2996-3009

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 25883113

    View Full Text